CADUET Drug Patent Profile
✉ Email this page to a colleague
When do Caduet patents expire, and what generic alternatives are available?
Caduet is a drug marketed by Pharmacia and is included in one NDA.
The generic ingredient in CADUET is amlodipine besylate; atorvastatin calcium. There are fifty drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the amlodipine besylate; atorvastatin calcium profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Caduet
A generic version of CADUET was approved as amlodipine besylate; atorvastatin calcium by MYLAN on November 29th, 2013.
Summary for CADUET
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
Raw Ingredient (Bulk) Api Vendors: | 133 |
Clinical Trials: | 13 |
Patent Applications: | 2,513 |
Formulation / Manufacturing: | see details |
Drug Prices: | Drug price information for CADUET |
Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for CADUET |
What excipients (inactive ingredients) are in CADUET? | CADUET excipients list |
DailyMed Link: | CADUET at DailyMed |
Paragraph IV (Patent) Challenges for CADUET
Tradename | Dosage | Ingredient | Strength | NDA | ANDAs Submitted | Submissiondate |
---|---|---|---|---|---|---|
CADUET | Tablets | amlodipine besylate; atorvastatin calcium | 2.5 mg/40 mg | 021540 | 1 | 2009-09-17 |
CADUET | Tablets | amlodipine besylate; atorvastatin calcium | 5 mg/80 mg | 021540 | 1 | 2009-04-07 |
CADUET | Tablets | amlodipine besylate; atorvastatin calcium | 5 mg/10 mg 5 mg/20 mg 5 mg/40 mg 10 mg/10 mg 10 mg/20 mg 10 mg/80 mg | 021540 | 1 | 2006-12-29 |
US Patents and Regulatory Information for CADUET
Expired US Patents for CADUET
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Pharmacia | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-005 | Jan 30, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Pharmacia | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-003 | Jan 30, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Pharmacia | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-008 | Jan 30, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Pharmacia | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-007 | Jan 30, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Pharmacia | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-003 | Jan 30, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
Pharmacia | CADUET | amlodipine besylate; atorvastatin calcium | TABLET;ORAL | 021540-002 | Jan 30, 2004 | ⤷ Try a Trial | ⤷ Try a Trial |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for CADUET
See the table below for patents covering CADUET around the world.
Country | Patent Number | Title | Estimated Expiration |
---|---|---|---|
Morocco | 26535 | ⤷ Try a Trial | |
Poland | 250767 | ⤷ Try a Trial | |
Canada | 2301732 | COMBINAISONS THERAPEUTIQUES (THERAPEUTIC COMBINATIONS) | ⤷ Try a Trial |
Japan | 2007137903 | SALT OF [R-(R*,R*)]-2-(4-FLUOROPHENYL)-beta,delta-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-[(PHENYLAMINO)CARBONYL]-1H-PYRROLE-1-HEPTANOIC ACID | ⤷ Try a Trial |
Georgia, Republic of | P20002029 | (54) Crystalline [R-(R*,R*,]-2-(4-Fluorophenyl)-Beta,Delta-Dihydroxy-5-(1-Methyl-Ethyl)-3-Phenyl-4-{Phenylamino) Carbonyl} - 1H - Pyrrole - 1 - Heptanoic Acid Hemi Calcium Salt (Atorvastatin) | ⤷ Try a Trial |
Latvia | 5235 | 1,4-dihidropiridina atvasinajumu vai to skabju aditivo saju iegusanas panemiens | ⤷ Try a Trial |
>Country | >Patent Number | >Title | >Estimated Expiration |
Supplementary Protection Certificates for CADUET
Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
---|---|---|---|---|
0089167 | SPC/GB93/046 | United Kingdom | ⤷ Try a Trial | SPC/GB93/046: 20040307 |
0502314 | SPC/GB11/010 | United Kingdom | ⤷ Try a Trial | PRODUCT NAME: THE COMBINATION OF A) TELMISARTAN, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, AND B) AMLODIPINE, OPTIONALLY IN THE FORM OF PHARMACEUTICALLY ACCEPTABLE SALTS, ESPECIALLY AMLODIPINE BESYLATE; REGISTERED: UK EU/1/10/648/001 20101007; UK EU/1/10/648/002 20101007; UK EU/1/10/648/003 20101007; UK EU/1/10/648/004 20101007; UK EU/1/10/648/005 20101007; UK EU/1/10/648/006 20101007; UK EU/1/10/648/007 20101007; UK EU/1/10/648/008 20101007; UK EU/1/10/648/009 20101007; UK EU/1/10/648/010 20101007; UK EU/1/10/648/011 20101007; UK EU/1/10/648/012 20101007; UK EU/1/10/648/013 20101007; UK EU/1/10/648/014 20101007; UK EU/1/10/648/015 20101007; UK EU/1/10/648/016 20101007; UK |
1003503 | 05C0048 | France | ⤷ Try a Trial | PRODUCT NAME: AMLODIPINE OU UN DE SES SELS D?ADDITION D?ACIDES PHARMACAUTIQUEMENT ACCEPTABLES/ ATORVASTATINE OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: NL 29929 DU 20050707; REGISTRATION NO/DATE AT EEC: NL 29929 DU 20050707 |
0503785 | CA 2011 00026 | Denmark | ⤷ Try a Trial | PRODUCT NAME: A COMBINATION OF OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, AND AMLODIPINE BESYLATE AND HYDROCHLOROTHIAZIDE; NAT. REG. NO/DATE: 46260-46269 (DK) 20110323; FIRST REG. NO/DATE: DE 79810.00.00 20101216 |
0503785 | C300375 | Netherlands | ⤷ Try a Trial | PRODUCT NAME: COMBINATIE VAN OLMESARTAN MEDOXOMIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZOUT EN AMLODIPINEBESILAAT; REGISTRATION NO/DATE: RVG100984, RVG100986-87, RVG100989-91, RVG100993-95 20080819 |
1507558 | 2012/018 | Ireland | ⤷ Try a Trial | PRODUCT NAME: ALISKIREN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AMLODIPINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND HYDROCHLOROTHIAZIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF.; NAT REGISTRATION NO/DATE: EU/1/11/730/001-060 20111122; FIRST REGISTRATION NO/DATE: SWITZERLAND 6167801-6167805 20110705 |
>Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |